Trial achieved its primary endpoint of pathological Complete Response Rate Trial achieved its secondary endpoint in operability (R0 rate) NBTXR3 demonstrated significant superiority and clinical …
Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival Genmab A/S (Nasdaq Copenhagen: GEN) announced today that …
Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy at 40 Weeks Ultragenyx Pharmaceutical …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
